The dipeptidyl peptidase-4 (DPP4) inhibitors are a novel class of antidiabetic drugs with a good safety profile and which are now being considered in some algorithms for the treatment of type 2 diabetes mellitus (T2DM). The gene discussed is DPP4; the disease is diabetes mellitus.